NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.20+₹41.20 (+2.34%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · GRANULES.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Granules India Limited’s forward annual dividend is ₹1.75 per share, paid annual. The forward yield is 0.21% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Granules India Limited’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of ₹8.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Granules India Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 28, 2025 | ₹5.15-1.9% vs estimate | ₹11.97B-1.46% vs estimate |
|---|
| Q3 2025 | Jan 24, 2025 | ₹4.90+6.52% vs estimate | ₹11.38B+3.69% vs estimate |
|---|
| Q2 2025 | Nov 6, 2024 | ₹4.00+3.9% vs estimate | ₹9.67B-8.71% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,802.20+₹41.20 (+2.34%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹1,235.50+₹51.10 (+4.31%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 1.11% below the high.
₹1,355.40+₹10.40 (+0.77%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
₹1,376.40+₹18.40 (+1.35%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 13.61% below the high.
₹1,678.10+₹18.20 (+1.1%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.56% below the high.
₹2,008.50+₹18.60 (+0.93%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 20.6% below the high.
₹1,929.00+₹2.80 (+0.15%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.35% below the high.
₹2,361.10-₹15.00 (-0.63%)
Caplin Point Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 21.03% below the high.
